Synthesis of 4b.
To a solution of 11-azido-3,6,9-trioxaundecanoic acid (100 mg, 0.429 mmol) in MeCN (1.0 mL) was added N-hydroxysuccinimide (52.0 mg, 0.450 mmol) and EDC・HCl (90.4 mg, 0.472 mmol). The reaction mixture was stirred for 3 h at room temperature, and was added to a solution of miniPEG TM ・ TFA (119 mg, 0.429 mmol) and N,N'-diisopropylethylamine, DIEA (186 µL, 1.07 mmol) in MeCN (600 µL). The reaction mixture was stirred for 1.5 h at room temperature, quenched with AcOH (100 µL), and concentrated in vacuo. The resulting residue was purified by RP-HPLC using a semi-preparative column at a 
Synthesis of 4c.
To a solution of 4b obtained above (50.0 mg, 0.132 mmol) in MeCN/H 2 O (9 : 1, v/v, 2.0 mL) was added N-hydroxysuccinimide (16.7 mg, 0.145 mmol) and EDC・HCl (27.8 mg, 0.145 mmol). The reaction mixture was stirred for 2 h at room temperature, and was added to a solution of miniPEG TM ・TFA (38.5 mg, 0.139 mmol) and DIEA (57 µL, 0.33 mmol) in H 2 O (500 µL). The reaction mixture was stirred for 2.5 h at room temperature, quenched with AcOH (100 µL), and concentrated in vacuo. The resulting residue was purified by RP-HPLC using a semi-preparative column at a flow rate of 3 mL/min with a linear gradient of MeCN/0.1%TFA (10-30% for 80 min) to obtain 4c (67.0 mg, 87% 
Synthesis of 4d.
To a solution of 4c obtained above (17.8 mg, 34.0 µmol) in MeCN/H 2 O (9 : 1, v/v, 150 µL) was added N-hydroxysuccinimide (4.1 mg, 36 µmol) and EDC・HCl (7.2 mg, 37 µmol). The reaction mixture was stirred for 2.5 h at room temperature, and was added to a solution of miniPEG TM ・TFA (9.4 mg, 34 µmol) and DIEA (15 µL, 85 µmol) in 50%
MeCN/H 2 O (100 µL). The reaction mixture was stirred for 2 h at room temperature, quenched with AcOH (30 µL), and concentrated in vacuo. The resulting residue was purified by RP-HPLC using a semi-preparative column at a flow rate of 3 mL/min with a linear gradient of MeCN/0.1%TFA (10-30% for 80 min) to obtain 4d (14.0 mg, 62% 
Synthesis of 1a.
To a solution of 11-azido-3,6,9-trioxaundecanoic acid (4.5 mg, 19.3 µmol) in MeCN (200 µL) was added N-hydroxysuccinimide (2.3 mg, 20 µmol) and EDC・HCl (4.0 mg, 21 µmol). The reaction mixture was stirred for 2 h at room temperature, and was added to a solution of cyclo-(Arg-Gly-Asp-DTyr-Lys) (10.0 mg, 16.1 µmol) and DIEA (8.4 µL, 48 µmol) in H 2 O (50 µL). The reaction mixture was stirred for 2 h at room temperature, quenched with AcOH (30 µL), and concentrated in vacuo. The resulting residue was purified by RP-HPLC using a preparative column at a flow rate of 7 mL/min with a linear gradient of MeCN/0.1%TFA (10-30% for 80 min) to obtain 1a (6.8 mg, 51% 
Synthesis of 1b.
To a solution of 4b obtained above (10.0 mg, 26.4 µmol) in MeCN/H 2 O (97 : 3, v/v, 300 µL) was added N-hydroxysuccinimide (3.2 mg, 28 µmol) and EDC・HCl (5.6 mg, 29 µmol). The reaction mixture was stirred for 1.5 h at room temperature, and was added to a solution of cyclo-(Arg-Gly-Asp-DTyr-Lys) (16.3 mg, 26.4 µmol) in 40% MeCN/H 2 O (150 µL) and DIEA (14 µL, 79 µmol). The reaction mixture was stirred for 3 h at room temperature, quenched with AcOH (50 µL), and concentrated in vacuo. The resulting residue was purified by RP-HPLC using the preparative column at a flow rate of 7 mL/min with a linear gradient of MeCN/0.1%TFA (13-33% for 80 min) to obtain 1b (9.1 mg, 35% 
Synthesis of 1c.
To a solution of 4c obtained above (5.5 mg, 11 µmol) in MeCN/H 2 O (9 : 1, v/v, 150 µL) was added N-hydroxysuccinimide (1.3 mg, 11 µmol) and EDC・HCl (2.2 mg, 11 µmol). The reaction mixture was stirred for 2 h at room temperature, and was added to cyclo-(ArgGly-Asp-DTyr-Lys) (5.0 mg, 8.1 µmol) and DIEA (4.2 µL, 24 µmol). The reaction mixture was stirred for 2 h at room temperature, quenched with AcOH (20 µL), and diluted with H 2 O (150 µL). The mixture was purified by RP-HPLC using the semi-preparative column at a flow rate of 3 mL/min with a linear gradient of MeCN/0.1%TFA (13-33% for 80 min) to obtain 1c (2.9 mg, 32%). HRMS calcd for C 47 
Synthesis of 1d.
To a solution of 4d (10.0 mg, 15.0 µmol) in MeCN/H 2 O (9 : 1, v/v, 240 µL) was added N-hydroxysuccinimide (1.8 mg, 16 µmol) and EDC・HCl (3.2 mg, 17 µmol). The reaction mixture was stirred for 1.5 h at room temperature, and was added to cyclo-(Arg-GlyAsp-DTyr-Lys) (9.3 mg, 15 µmol) and DIEA (7.8 µL, 45 µmol). The reaction mixture was stirred for 2 h at room temperature, quenched with AcOH (20 µL), and concentrated in vacuo. The resultant residue was purified by RP-HPLC using the preparative column at a flow rate of 7 mL/min with a linear gradient of MeCN/0.1%TFA (13-33% for 80 min) to obtain 1d (9.0 mg, 47%). HRMS calcd for C 53 
Synthesis of 6.
To a solution of 5 1 (32.0 mg, 83.0 µmol) in MeCN (1.0 mL) was added miniPEG-3 TM ・TFA (40.0 mg, 0.125 mmol) and DIEA (51 µL, 0.29 mmol). The reaction mixture was stirred for 3 h at room temperature, quenched with AcOH (200 µL), and concentrated in vacuo. The resultant residue was purified by RP-HPLC using the semi-preparative column at a flow rate of 3 mL/min with a linear gradient of MeCN/0.1%TFA (35-60% for 80 min) to obtain 6 (37.6 mg, quant To a solution of Boc-Lys (2.5 mg, 10 µmol) in DMF/H 2 O (250/120 µL) was added 5(6)-carboxytetramethylrhodamine succinimidyl ester (as two regioisomers, purchased from Life technologies, C1171, 5.0 mg, 9.5 µmol) and DIEA (4.9 µL, 28 µmol). The reaction mixture was stirred for 3 h at room temperature, quenched by AcOH (50 µL), and purified by RP-HPLC using the semi-preparative column at a flow rate of 3 mL/min with a linear gradient of MeCN/0.1%TFA (25-50% for 80 min) to obtain Boc-Lys(TAMRA) (5.7 mg). BocLys(TAMRA) thus obtained was dissolved in TFA (200 µL) and the reaction mixture was stirred for 10 min at room temperature. After removal of excess TFA with N 2 gas, the resultant residue was dissolved in H 2 O, and lyophilized to obtain Lys(TAMRA)・TFA (5.4 mg, 85%) as a mixture of TAMRA regioisomers. HRMS calcd for C 31 
Synthesis of 7.
To a solution of 6 (7.0 mg, 15 µmol) in 90% MeCN (200 µL) was added Nhydroxysuccinimide (1.9 mg, 17 µmol) and EDC・HCl (3.2 mg, 17 µmol). The reaction mixture was stirred for 2 h at room temperature, and was added to Lys(TAMRA) prepared above (8.6 mg, 13 µmol) and DIEA (8.9 µL, 64 µmol). The reaction mixture was stirred for 1 h at room temperature, quenched with AcOH (30 µL), and concentrated in vacuo. The residue was purified by RP-HPLC using the semi-preparative column at a flow rate of 3 mL/min with a linear gradient of MeCN/0.1%TFA (30-50% for 80 min) to obtain 7 (14 mg, quant) as a 
Synthesis of 8.
To a solution of 7 obtained above (8.9 mg, 9.0 µmol) in DMF (200 µL) was added N-hydroxysuccinimide (2.1 mg, 18 µmol) and EDC・HCl (10.3 mg, 53.7 µmol). The solution was stirred for 1.5 h at room temperature, and the mixture was directly purified by RP-HPLC using the semi-preparative column at a flow rate of 3 mL/min with a linear gradient of MeCN/0.1%TFA (30-60% for 80 min) to obtain 8 (6.7 mg, 68%) as a mixture of regioisomers. 
Synthesis of 2a.
To a solution of 9a 2 (3.0 mg, 1.2 µmol) in MeOH/H 2 O (2 : 1, v/v, 1 mL) was added 10% palladium on carbon (wet with 55% H 2 O, 320 µg). After the reaction mixture was stirred under H 2 atmosphere for 4.5 h, the catalyst was removed by filtration, and concentrated in vacuo. The residue was dissolved in H 2 O, and lyophilized to obtain the amine 10a (3.4 mg, quant), which was used for the reaction with 8 without further purification. HRMS calcd for C 95 H 159 N 9 O 65 ([M+2H] 2+ ) 1232.9707, found 1232.9750. To a solution of 8 (1.1 mg, 970 nmol) in DMF (50 µL) was added a solution of 10a (1.2 mg, 480 nmol) in 0.1 M sodium phosphate buffer (pH 7.0, 100 µL). The reaction mixture was stirred for 25 h at room temperature, quenched with 50% AcOH, and purified by RP-HPLC using the semi-preparative column at a flow rate of 3 mL/min with a linear gradient of MeCN/0.1%TFA (30-60% for 80 min) to obtain 2a (1.1 mg, 66%) as a mixture of TAMRA regioisomers. HRMS calcd for C 151 
Synthesis of 2b.
To a solution of 9b 2 (3.2 mg, 1.68 µmol) in MeOH/H 2 O (2 : 1, v/v, 500 µL) was added 10% palladium on carbon (wet with 55% H 2 O, 320 µg). After the reaction mixture was stirred under H 2 atmosphere for 4 h, the catalyst was removed by filtration, and concentrated in vacuo. The residue was dissolved with H 2 O, and lyophilized to obtain the corresponding amine 10b (3.0 mg, 95%), which was used for the reaction with 8 without further purification. 
Synthesis of cyclo-[Arg-Gly-Asp-DTyr-Lys(TAMRA)] (3).
To a solution of cyclo-(Arg-Gly-Asp-DTyr-Lys) (1.2 mg, 1.9 µmol) in DMF (50 µL) was added 5(6)-carboxytetramethylrhodamine-OSu (1.0 mg, 2.0 µmol) and DIEA (1.3 µL, 7.5 µmol). The mixture was stirred for 3.5 h at room temperature, quenched with AcOH (10 µL), and purified by RP-HPLC using the semi-preparative column at a flow rate of 3 mL/min with a linear gradient of MeCN/0.1%TFA (17-37% for 80 min) to obtain 3 (2.1 mg, quant) as a mixture of the TAMRA regioisomers. HRMS calcd for C 52 H 62 N 11 O 12 ([M+H] + ) 1032.4574, found 1032.4600 for isomer t R : 14.3 min, 1032.4609 for isomer t R : 16.0 min (flow rate of 1 mL/min with a linear gradient from 10 to 60% MeCN/0.1%TFA for 25 min using the analytical column). Preparation of authentic sample of "clicked" product between 1a and 2a.
To a solution of 2a (0.77 mg, 0.33 µmol) in PBS (50 µL) was added 1a (0.22 mg, 0.26 µmol. The reaction mixture was stirred for 1.5 h at room temperature, and purified by RP-HPLC using the semi-preparative column at a flow rate of 3 mL/min with a linear gradient of MeCN/0.1%TFA (20-50% for 80 min) to obtain the clicked product (0.4 mg for the isomer t R : 17.8 min, 0.6 mg for the isomer t R : 17.2 min LC-MS/MS analysis of clicked products (1a+2a) from cell surface HUVECs, which were treated with 1a and 2a according to the established procedure, were washed with PBS twice, and treated with KCl-HCl buffer (pH 2.0, 1.0 mL) on ice, three times for 1 min to dissociate the clicked products from the cell surface. The collected KClHCl buffer solution was combined and centrifuged. The supernatant was then lyophilized for MS analysis. The sample was subjected to nano-liquid chromatography-mass spectrometry. The clicked product were purified using nano ESI spray column (100 mm length ×75 µm inside diameter, 3 µm, NTCC analytical column C18, Nikkyo Technos Co., Ltd., Tokyo, Japan) that was equilibrated with A buffer (0.1% aqueous formic acid) and eluted with a linear gradient of 35% buffer B (0.1% formic acid in 100% acetonitrile) over 10 min at a flow rate of 300 nl/min (Easy nLC, Thermo Fisher Scientific). The mass spectrometer (Q-Exactive, Thermo Fisher Scientific) was operated in the positive-ion mode, and the MS/MS spectra were acquired in a data-dependent TOP10 method or a targeted MS/MS (m/z = 1425.58) method. Figure S17. Importance of using low-affinity ligand of the surface receptor on the target cell A for highly selective imaging. In comparison with the Figure 1b using the low-affinity ligand "D", when applying the high-affinity ligand, e.g., ligand "E", could bind and stick to the other cells ( Figure S17d ), e.g., "cell C" expressing this receptor, so that the imaging selectivity is reduced. Flow cytometer. HUVECs (1.2 × 10 5 cells, 1 mL) were plated onto a 24-well microplate (Iwaki) and incubated in the EBM TM -2 cell culture medium for 24 h at 37°C under 5% CO 2 . After complete adhesion, the cells were washed with the cell culture medium and treated with the cyclic RGD peptide 1a (50 µM, 600 µl/well) for 15 min at room temperature (25°C) before washing with the EBM TM -2 cell culture medium (triple washing, 200 µl). The cells were treated with the TAMRA-glycan derivative 2a (50 µM, 600 µl/well) for 30 min at 4°C. After washing with PBS (triple washing, 200 µl), the cells were treated with 2 mM EDTA (200 µl/well) at 37°C for 10 min and then centrifuged at 3,000 rpm (800 × g) for 5 min at 4°C. After removal of the supernatant, the cells were washed with PBS (400 µl) and centrifuged at 3,000 rpm for 5 min at 4°C. This washing cycle was repeated, and the cells were suspended in PBS (400 µl) and subjected to fluorescence analysis with a guava easyCyte (Merck Millipore) flow cytometer using 488 nm laser excitation and a 583 nm emission filter. Live cells (10,000 cells/sample) for the detection of cellular fluorescence intensity were quantified based on forward-scattering and side-scattering analyses. siRNA transfection experiment.
HUVECs were seeded onto 8-well chamber slides coated with type I collagen (2 × 10 4 cells/well). After siRNA transfection followed by treatment with the probes 1a and 2a, the cells were fixed with 4% paraformaldehyde and blocked with 5% goat serum in PBS. The cells were incubated with rabbit anti-PECAM (H-300; 1:50 dilution; Santa Cruz Biotechnology) followed by treatment with Alexa Fluor 488-conjugated anti-rabbit IgG (1:100 dilution; Invitrogen). DAPI was used as a counterstain for nuclei. The samples were mounted in CC/Mount and visualized under the FV1000-D laser scanning confocal microscope (Olympus).
For Western blot analysis, HUVECs were seeded in culture dishes (10 cm). On reaching 30-50% confluence, the cells were transfected in 9 mL of medium containing Lipofectamine RNAiMAX (12 µL, Invitrogen) and PECAM-1 siRNA (72 pmol; Qiagen) and non-targeted siRNA, siControl, for 24 h. After transfection, whole cell proteins were obtained using RIPA buffer containing a protease inhibitor mixture (Roche Applied Science). The lysates (15 µg of proteins) were separated by SDS-PAGE using 4-20% gradient gels and transferred to a nitrocellulose membrane. The membrane was incubated with an anti-PECAM antibody (1:1000 dilution; Santa Cruz Biotechnology) and an anti-GAPDH antibody (1:1000 dilution; Millipore) as a primary antibody at 4 o C overnight. GAPDH was an internal reference. The primary antibodies were detected with horseradish peroxidase-conjugated donkey anti-goat and anti-mouse IgG (1:3000 and 1:1000 dilution, respectively; Jackson ImmunoResearch). The antibody-protein complexes were visualized by a Western Lightning ECL Pro (Perkin Elmer). The protein bands were analyzed using a Luminoimage Analyzer LAS-1000 PLUS (Fuji Film). Figure S26 . Cell imaging and Western blot after siRNA transfection. a, the pre-targeting imaging was performed using 1a and 2a (red) after transfection with siRNA against PECAM (siPECAM) or non-targeted siRNA (siControl). The cells were fixed, stained with anti-PECAM (green), and DAPI (blue). The scale bar indicates 20 µm. b, The PECAM knockdown by siRNA transfection was evaluated by Western blot analysis. GAPDH was an internal control.
